Search
Gemeprost
go.drugbank.com/drugs/DB08964ApprovedWithdrawnIt is not FDA-approved but available in Japan marketed as Preglandin.
Bivalirudin
go.drugbank.com/drugs/DB00006ApprovedInvestigationalBecause it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure.
Potassium acetate
go.drugbank.com/drugs/DB14498ApprovedMixtures: ELETTROLITICA DI MANTENIMENTO CON GLUCOSIO FKI, ELETTROLITICA DI MANTENIMENTO CON GLUCOSIO FKIYKP-1358
go.drugbank.com/drugs/DB06109ExperimentalYKP1358 is a novel serotonin (5-HT2A) and dopamine (D2) antagonist that has demonstrated potent activity in animals that relates to both positive and negative symptoms of schizophrenia.
Categories: Dopamine D2 Receptor AntagonistsCobalt
go.drugbank.com/drugs/DB14574ApprovedWithdrawnDeficiency in animals leads to anemia; its excess in humans can lead to erythrocytosis. … Except for radioactive forms of cobalt and cobalamin, the FDA withdrew its approval for the use of drug products containing cobalt salts.[L43942]
Epoprostenol
go.drugbank.com/drugs/DB01240ApprovedInvestigationalA prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary...
Vilazodone
go.drugbank.com/drugs/DB06684ApprovedInvestigationalVilazodone was given FDA approval on January 21, 2011[L6046,A177622].
Seladelpar
go.drugbank.com/drugs/DB12390ApprovedInvestigational[L51149] On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis,[L51154] which is a condition associated with aberrant bile acid metabolism
Chloroquine
go.drugbank.com/drugs/DB00608ApprovedInvestigationalVet approvedChloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria. … [L14312]** Chloroquine was granted FDA Approval on 31 October 1949.[L12054]
Bimekizumab
go.drugbank.com/drugs/DB12917ApprovedInvestigationalBimekizumab was also granted FDA approval on October 18, 2023.[L48551] … Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis.